Hubei Goto Biopharm Group Co., Ltd. (SHE:300966)
China flag China · Delayed Price · Currency is CNY
23.87
-0.21 (-0.87%)
Sep 2, 2026, 3:04 PM CST

Hubei Goto Biopharm Group Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
-100.56-73.36-27.5923.0140.2178.33
Depreciation & Amortization
132.09115.4143.2428.2127.2323.36
Other Amortization
3.353.333.312.830.81-
Loss (Gain) From Sale of Assets
01.44-0.11-0.170.01-
Asset Writedown & Restructuring Costs
1.763.7910.462.230.963.47
Loss (Gain) From Sale of Investments
3.580.290.35-0.170.04-0
Provision & Write-off of Bad Debts
3.766.084.224.454.87-
Other Operating Activities
52.7649.6825.0919.7911.527.76
Change in Accounts Receivable
13.6725.478.56-60.59-34.6620.23
Change in Inventory
-68.81-99.52-43.31-9.76-60.43-173.33
Change in Accounts Payable
48.6534.6-29.8362.04-6.5103.58
Change in Other Net Operating Assets
-0.92-1.66-0.031.69--
Operating Cash Flow
69.3141.04-20.5968.13-24.0458
Operating Cash Flow Growth
-----330.46%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-86.16-166.33-311.61-409.25-407.94-90.91
Sale of Property, Plant & Equipment
0.080.180.12-0.13-
Investment in Securities
---15.02-48.5-14.5
Other Investing Activities
--17.16-8.110-
Investing Cash Flow
-86.08-166.14-294.34-402.35-456.3-105.41

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Short-Term Debt Issued
--32---
Long-Term Debt Issued
-468.38723.59323.2953.57160
Total Debt Issued
359.35468.38755.59323.2953.57160
Long-Term Debt Repaid
--326.06-434.2-319.88-250.44-156.77
Total Debt Repaid
-324.66-326.06-434.2-319.88-250.44-156.77
Net Debt Issued (Repaid)
34.69142.32321.393.32703.123.23
Issuance of Common Stock
-----208.16
Repurchase of Common Stock
-23.89-21.97----
Common Dividends Paid
-32.26-29.83-25.69-6.09-26.91-7.58
Other Financing Activities
-7.12-0.3323.718.3737.083.18
Financing Cash Flow
-28.5890.19319.415.59713.3207

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-0.38-0.06-0.56-0.320.28-0.44
Net Cash Flow
-45.74-34.983.92-318.94233.23159.16

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-16.85-125.29-332.2-341.12-431.98-32.91
Free Cash Flow Growth
------
Free Cash Flow Margin
-2.59%-20.67%-61.91%-60.23%-71.45%-5.57%
Free Cash Flow Per Share
-0.15-1.09-2.89-2.97-3.76-0.31
Levered Free Cash Flow
--160.41-294.8910.86-403.28-57.11
Unlevered Free Cash Flow
--130.58-280.1919.1-394.73-53.87

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Interest Paid
0.270.270.3---
Cash Income Tax Paid
--33.08-47.25-39.05-13.8117.33
Change in Working Capital
-27.44-65.63-79.56-12.04-109.68-54.91